Arthritis
Cytokine Announces Oral Efficacy of Anti-Cytokine Semapimod
Published in Medical Patent Business Week, November 16th, 2007
Cytokine PharmaSciences, Inc. (CPSI) announced development of an orally active form of semapimod, its synthetic anti-cytokine compound. Semapimod is a potential treatment for inflammatory and autoimmune diseases including rheumatoid arthritis, Crohn's and psoriasis. The compound has previously been tested in clinical trials only as an intravenous infusion and the newly developed oral form should significantly enhance its acceptability to patients and physicians.
Semapimod is a synthetic guanylhydrazone that inhibits the activity of various kinases, including Raf kinase, a key enzyme in the MAPK/ERK signal transduction pathway. Semapimod's inhibition of Raf-kinase...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
More Articles from Medical Patent Business Week
- Algorithms
Entry of Biogenerics and Decreasing Use of Amgen's Epogen and Johnson & Johnson's Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016 - Algorithms
Scientists at Dongguk University detail research in algorithms - Antisense Technology
Ryogen Gets Patent on Soluble Aminopeptidase P Gene - Atherectomy
Spectranetics Reports Third Quarter Revenue of $21.2 Million as Atherectomy Product Sales Increase 42% - Bioinformatics
Cell Signaling Technology Announces the Availability of PhosphoScan(R) Profiling Technology and PhosphoSite(R) Knowledgebase to Academic Researchers - Biomedicine
BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant - More from this issue of Medical Patent Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
